ArticleFrontiers in immunology2021
Co-Expression of FOXP3FL and FOXP3Δ2 Isoforms Is Required for Optimal Treg-Like Cell Phenotypes and Suppressive Function.
Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 31 citations in OpenAlex.
- First Comprehensive Analysis of Full-Length and Δ2 Foxp3 Isoforms Distribution in PBMCs from Healthy Volunteers.Biomolecules · 2026Article
- Defects in CD8bioRxiv : the preprint server for biology · 2026Article
- Beyond the Classical Triad: Atypical Presentations and Regulatory T Cell Phenotyping in a Cohort of IPEX Patients.Journal of clinical immunology · 2025Article
- Reprogramming intratumoral TScience immunology · 2025Article
- Clinical Relevance ofInternational journal of molecular sciences · 2025Article
- Full-Length Transcriptome Sequencing Reveals Treg-Specific Isoform Expression upon Activation.International journal of molecular sciences · 2025Article
- Modulation of NCX1 expression in monocytes associates with multiple sclerosis progression.Heliyon · 2025Article
- Review
- Regulatory T cell therapy for myeloperoxidase-specific anti-neutrophil cytoplasmic antibody associated vasculitis.Frontiers in immunology · 2025Review
- A splice of life: the discovery, function, and clinical implications of FOXP3 isoforms in autoimmune disease.International immunology · 2024Review
- Mini-Review: Tregs as a Tool for Therapy-Obvious and Non-Obvious Challenges and Solutions.Cells · 2024Review
- FOXP3 splice variant expression in males and females in healthy populations and in kidney transplant recipients.Scientific reports · 2024Article
- Induction of FoxP3 Pre-mRNA Alternative Splicing to Enhance the Suppressive Activity of Regulatory T Cells from Amyotrophic Lateral Sclerosis Patients.Biomedicines · 2024Article
- Expression of full-length FOXP3 exceeds other isoforms in thymus and stimulated CD4 + T cells.Journal of clinical immunology · 2024Article
- Genetic engineering of regulatory T cells for treatment of autoimmune disorders including type 1 diabetes.Diabetologia · 2024Review
- FOXP3 full length splice variant is associated with kidney allograft tolerance.Frontiers in immunology · 2024Article
- Article
- Non-canonical NFKB signaling endows suppressive function through FOXP3-dependent regulatory T cell program.Heliyon · 2023Article
- The Role of Regulatory T Cells in the Onset and Progression of Primary Sjögren's Syndrome.Cells · 2023Review
- Rare immune diseases paving the road for genome editing-based precision medicine.Frontiers in genome editing · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
FOXP3 is the master transcription factor in both murine and human FOXP3
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.